Cardiac amyloidosis is a complex and often underdiagnosed pathological condition, which poses significant challenges in both its detection and management. Molecular imaging has gained interest in the latest year, due to its capability to allow for an early and precise diagnosis of cardiac amyloidosis as well as for its characterization. Furthermore, recent evidence show the potential for a prognostic stratification. In fact, molecular imaging, including positron emission tomography (PET) and single photon emission computed tomography (SPECT), enables specific insights in the processes underlying amyloid deposition within the heart, thus providing important information on disease progression and treatment response. This collection aims to explore pre-clinical research and clinical applications of molecular imaging in the scenario of cardiac amyloidosis, highlighting its important role in improving patients’ outcome and guiding therapeutic strategies.